Printer Friendly

AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS

 SAN DIEGO, Jan. 29 /PRNewswire/ -- Agouron Pharmaceuticals Inc. (NASDAQ-NMS: AGPH) today announced a net loss for the three and six months ended Dec. 31, 1992, of $3,050,000, or $.44 per common share, and $5,526,000, or $.80 per share, respectively. The net loss recorded in each comparable period of the prior fiscal year was $2,480,000, or $.40 per share, and $4,587,000, or $.83 per share.
 Agouron Pharmaceuticals Inc. is a pioneer and leader of a technology permitting the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS and other serious diseases.
 AGOURON PHARMACEUTICALS INC.
 Summary Financial Information
 (In thousands, except per share amounts)
 Three months ended Six months ended
 Dec. 31, Dec. 31,
 1992 1991 1992 1991
 Statement of
 Operations Data:
 (Unaudited)
 Total revenues $1,833 $1,477 $4,076 $2,573
 R&D spending $4,313 $3,195 $8,530 $5,872
 Net loss ($3,050) ($2,480) ($5,526) ($4,587)
 Net loss per share ($.44) ($.40) ($.80) ($.83)
 Wt. avg. no. shares 6,932 6,207 6,919 5,544
 Dec. 31, June 30,
 1992 1992
 (Unaudited)
 Balance Sheet Data:
 Current assets $37,249 $40,173
 Total assets $42,405 $45,625
 -0- 1/29/93
 /CONTACT: Steven S. Cowell, VP and CFO, or Donna Nichols, director of corporate communications, of Agouron Pharmaceuticals, 619-622-3000/
 (AGPH)


CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: ERN

EH-JL -- SD001 -- 0927 01/29/93 16:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 29, 1993
Words:273
Previous Article:MARITRANS PARTNERS L.P. ANNOUNCES RESULTS FOR QUARTER AND YEAR ENDED DEC. 31, 1992, MAILING OF PROXIES TO UNITHOLDERS ON CORPORATE CONVERSION
Next Article:DROUGHT CONTINUES TO DEPRESS IDAHO POWER EARNINGS
Topics:


Related Articles
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1992 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1993 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FISCAL 1995 FINANCIAL RESULTS
AGOURON PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS
Agouron Pharmaceuticals Reports Fourth Quarter and Fiscal 1997 Financial Results; Announces 2 For 1 Stock Split

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters